Evaluating Standardized Procedures for Low-Molecular-Weight Heparin Injections to Reduce Injection Site Complications in Cardiovascular Disease Patients

What this Trial Is About

This research aims to evaluate the impact of a standardized protocol for subcutaneous low-molecular-weight heparin LMWH injections on patients with cardiovascular disease. The study addresses concerns about complications such as bruising and pain at the injection site, which may result from improper injection techniques. The trial is designed to improve consistency in clinical practice for patients receiving LMWH injections. Participants are randomly assigned to one of two groups the control group, which receives the usual LMWH injection practice by nurses, and the intervention group, which follows a standardized injection protocol administered by nurses. This comparison allows researchers to assess whether the standardized method reduces injection site complications. Treatments are given subcutaneously, with injections administered twice daily as prescribed. During the study, participants will be monitored for bruising and pain at various time points up to 72 hours after injection. Researchers will also assess patient experience immediately after injections and evaluate communication competence before and after injections. The study involves follow-up visits to observe these outcomes, with a focus on safety and adherence. The trial is expected to conclude by early 2026.

The Effect of Standardizing Procedures for SC Injections of LMWH on Patients With CVD